Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. New England Compounding Pharmacy, Inc.
483
•New England Compounding Pharmacy, Inc.•April 16, 2002

New England Compounding Pharmacy, Inc. – FDA 483, Apr 16, 2002

Record Details

On April 9, 10, and 16, 2002, the FDA inspected New England Compounding Pharmacy, Inc. at 697 Waverly Street, issuing a Form 483 to Barry Cadden, R. Ph, Owner and Director of Pharmacy.

Observations included: 1. For Betamethasone Repository Injection (Betamethasone Acetate and Betamethasone Sodium Phosphate Suspension 6 mg/ml), a sterile product, bulk compounded product is sampled for sterility and endotoxin testing immediately after sterilization in a beaker. Individual vials are not filled until test results are received, which can take up to a week. During this period, the beaker and its contents are stored in a laminar flow hood, covered only by multiple layers of aluminum foil. 2. Samples taken immediately after autoclave sterilization are not representative of the product remaining in the original beaker for up to one week post-sampling. 3. The firm's autoclave cycle validation does not account for the autoclaved bulk product not being transfilled into final containers (vials) for up to one week. 4. Lot number 02012002@027 was generated in the computerized record-keeping system, but no associated records could be retrieved, making it impossible to determine if the lot was distributed without records or if its preparation was canceled without proper documentation.

Company
New England Compounding Pharmacy, Inc.
Inspection date
April 16, 2002
Product type
Drugs
Office
New England District Office
People
  • Kristina M. Joyce (Deputy Office Director, FDA/CDRH OHT3)
  • Mark Lookabaugh (Principal at Mark Lookabaugh Consulting | FDA Compliance Consulting)
View Company Profile

ID · 0b17acd0-4d61-4ce0-9b72-dcf50d86d687

Violation Codes3
21 CFR 211.100(a)21 CFR 211.67(a)21 CFR 211.42(c)(5)

Full citation text and observation details available on the Dashboard.

Other documents for New England Compounding Pharmacy, Inc.
  • 483 - 2003-02-10February 10, 2003

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore New England Compounding Pharmacy, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.